Half-year report · Q2
4578.TEDINET S100U5FO
Period2024-01-01 → 2024-06-30
Filed2024-08-02
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 56
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.11T | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥589.4bn | 2024-04-01 → 2024-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥2.02T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥947.5bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥499.2bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥126.3bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥34.3bn | 2024-04-01 → 2024-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥130.7bn | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥53.9bn | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥142.2bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥42.1bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥142.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥138.8bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥59.6bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥107.8bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥30.4bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥121.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥102.6bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.2bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥110.6bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥31.7bn | 2024-04-01 → 2024-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥105.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.4bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.66T | at 2024-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.36T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.31T | at 2023-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥993.9bn | at 2024-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥924.9bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.67T | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.47T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.62T | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.39T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.43T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥485.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥498.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥133.0bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥283.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥113.5bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥159.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥190.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥54.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥26.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.3bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥46.8bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥198.61 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥56.03 | 2024-04-01 → 2024-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥224.1 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥189.06 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥75.85 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| Equity ratio | 71.6% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.4% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-06-30 | ¥56.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-06-30 | ¥29.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥54.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-06-30 | ¥28.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥880m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-06-30 | ¥4.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-06-30 | ¥2.9bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-06-30 | −¥890m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-06-30 | −¥890m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥24.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-06-30 | −¥13.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥15.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2024-04-01 → 2024-06-30 | ¥8.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥15.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2024-04-01 → 2024-06-30 | ¥8.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥3m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥1m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥12.3bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2024-04-01 → 2024-06-30 | ¥8.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥271.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2024-04-01 → 2024-06-30 | ¥145.6bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥271.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2024-04-01 → 2024-06-30 | ¥145.6bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥15m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥8m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥37.3bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2024-04-01 → 2024-06-30 | ¥20.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥766.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2024-04-01 → 2024-06-30 | ¥407.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥766.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2024-04-01 → 2024-06-30 | ¥407.1bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥96.0bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2024-04-01 → 2024-06-30 | ¥16.2bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥1.11T |
| —segment total | revenue | 2024-04-01 → 2024-06-30 | ¥590.3bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥1.11T |
| —segment total | revenue external | 2024-04-01 → 2024-06-30 | ¥589.4bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-06-30 | ¥890m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥150.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-06-30 | ¥47.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-06-30 | ¥55.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥27.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥53.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥26.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥920m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-06-30 | ¥4.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥965m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥965m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥25.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥12.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥9m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥4m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥8.1bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥54m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥40m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥7.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥3.8bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥650.4bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥340.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥650.4bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥340.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥136.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥62.7bn |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥949.2bn |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥500.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥947.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥499.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥1.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥965m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥156.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥66.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 877
| Item | Context | Value | Unit |
|---|---|---|---|
| Intersegment revenue IFRS | CurrentQuarterDuration | － | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 407129000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 145603000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 8393000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 29177000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 590303000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -890000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration | 589412000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 16248000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 20537000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 7986000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2901000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 47673000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -13415000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration | 34258000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-08-02 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第17期中（自 2024年１月１日 至 2024年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)大塚ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Otsuka Holdings Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長兼CEO 樋口 達夫 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区神田司町二丁目９番地（同所は登記上の所在地であり、実際の業務は下記の最寄りの連絡場所で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03－6717－1410 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)財務会計部課長 小清水 裕之 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区港南二丁目16番４号 品川グランドセントラルタワー12階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03－6717－1410 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)財務会計部課長 小清水 裕之 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E21183 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45780 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)大塚ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Otsuka Holdings Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-06-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |